Playing with heart and soul...and genomes: Sports Implications and Applications of Personal Genomics

Whether the integration of genetic/omic technologies in sports contexts will facilitate player success, promote player safety, or spur genetic discrimination depends largely upon the game rules established by those currently designing genomic sports medicine programs. The integration has already begun, but there is not yet a playbook for best practices. Thus far discussions have focused largely on whether the integration would occur and how to prevent the integration from occurring, rather than how it could occur in such a way that maximizes benefits, minimizes risks, and avoids the exacerbation of racial disparities. Previous empirical research has identified members of the personal genomics industry offering sports-related DNA tests and previous legal research has explored the impact of collective bargaining in professional sports as it relates to the employment protections of the Genetic Information Nondiscrimination Act (GINA). Building upon that research and upon participant observations with specific sports-related DNA tests purchase from four direct-to-consumer companies in 2011 and broader personal genomics (PGx) services, this anthropological, legal, and ethical (ALE) discussion highlights fundamental issues that must be addressed by those developing personal genomic sports medicine programs, either independently or through collaborations with commercial providers. For example, the vulnerability of student athletes creates a number of issues that require careful, deliberate consideration. More broadly, however, this ALE discussion highlights potential sports-related implications (that ultimately might mitigate or, conversely, exacerbate racial disparities among athletes) of whole exome/genome sequencing conducted by biomedical researchers and clinicians for non-sports purposes. For example, the possibility that exome/genome sequencing of individuals who are considered to be non-patients, asymptomatic, normal, etc. will reveal the presence of variants of unknown significance in any one of the genes associated with hypertrophic cardiomyopathy (HCM), Long QT syndrome (LQTS), Marfan’s syndrome, and other conditions is not inconsequential and how this information is reported, interpreted, and used may ultimately prevent the individual from participation in competitive sports. Due to the distribution of genetic diversity that reflects our evolutionary and demographic history (including the discernible effects of restricted gene
flow and genetic drift associated with cultural constructs of race) and in recognition of previous policies for “leveling” the playing field in competitive sports based on “natural” athletic abilities, preliminary recommendations are provided to discourage genetic segregation of sports and to develop best practice guidelines for genomic sports medicine programs that will facilitate player success, promote player safety, and avoid genetic discrimination within and beyond the program.
Playing with Heart and Soul…and Genomes: Sports Implications and Applications of Personal Genomics

Introduction

In March 2013 the American College of Medical Genetics and Genomics (ACMG) and the American Academy of Pediatrics (AAP) announced a policy statement on genetic testing and screening of children (Friedman Ross et al. 2013). As shown in Table 1, the AAP and ACMG jointly and unequivocally opposed a number of practices regarding minors, including school-based genetic screening or testing, routine carrier screening for recessive conditions (such as sickle cell carrier status), and direct-to-consumer testing. Similarly, the AAP and ACMG cautioned against the expansion of newborn screening, warning that such practices may “give rise to ‘patients in waiting’: individuals with a genetic diagnosis who have no signs or symptoms and may remain asymptomatic for years or decades.” The need for genetic counseling was highlighted, specifically in the context of predictive testing (i.e. testing for “the presence of a mutation that will almost certainly give rise to clinical manifestations”), with the AAP and ACMG noting that such counseling is “essential to ensure that parents, guardians, and maturing minors fully understand the limits of genetic knowledge and treatment capabilities as well as the potential for psychological harm, stigmatization, and discrimination.” The AAP and ACMG also took positions on access to testing, timing of testing, and access to test results, as shown in Table 2, recognizing parents and children may have differing opinions. In doing so, the organizations emphasized the need to focus on the best medical interests of the child but recognized those interests are “embedded in and dependent on the interests of the family unit.”

Also in March 2013, the ACMG announced age-neutral recommendations (Green et al. 2013) for reporting of incidental findings in exome and genome sequencing (WES/WGS). Prompted by criticisms and perhaps also confusions (e.g. Heger 2013), the ACMG issued clarifications shortly thereafter (ACMG 2013). Notwithstanding the positions the ACMG affirmed with its joint statement with the AAP, the ACMG recommended the minimum reporting of incidental findings of any variants previously reported as “known” or “expected” to be pathogenic—regardless of the well-documented publication bias of positive results in the academic literature and regardless of the individual’s health—in “a set of 57 carefully chosen genes for pathogenic mutations that could indicate the presence of any of 24 disorders where
early intervention is likely to reduce or prevent serious morbidity or early mortality” (Green et al. 2013). The ACMG reaffirmed its concerns regarding an emerging class of “patients in waiting” who may face significant psychological burdens and exposure to unnecessary surveillance and diagnostic testing as the result of learning about incidental findings from WES/WGS. While the ACMG clarified that WES/WGS specifically of youth should be performed “only if there are clear clinical indications,” the organization noted that this recommendation to report to youth incidental findings of “a severe, actionable, pathogenic mutation” is not contradictory to or inconsistent with the organization’s prior recommendation made with the AAP (ACMG 2013).

**Sports Implications of Genomic Research and Medicine**

As shown in Table 3, among the 57 genes on the ACMG’s list for reporting of variants are a number of genes involved with cardiac conditions, including 11 genes reported to cause Hypertrophic Cardiomyopathy (HCM), three genes reported to cause Long QT Syndrome (LQTS), and seven genes reported to cause Marfan Syndrome (MFS) and related disorders. HCM (OMIM #192600) has an estimated prevalence of 1 in 500. The condition is clinically variable and genetically heterogeneous. At least 18 genes have been reported, including the 11 genes included on the ACMG list for reporting of incidental findings. Roughly 60-70% of cases of HCM are due to mutations in one or more of the 18 genes. Reliably distinguishing pathogenic variants from variants of unknown significance (VUS) and non-pathogenic variants in these genes presents a major challenge for genomic medicine (Maron, Maron, and Semsarian 2012). Notably, roughly 50% of adults diagnosed with HCM have a family history of either HCM or sudden death at a young age (e.g. GeneDx 2011a). HCM is the leading cause of sudden cardiac arrest in young individuals and athletes (e.g. Maron et al. 2009).

LQTS (OMIM #192500) has an estimated prevalence of more than 1 in 3000. Approximately 75% of the cases of LQTS are due to known genetic mutations. Like HCM, LQTS is genetically heterogeneous: while three genes are on the ACMG’s minimum list for reporting of incidental findings, more than 12 genes have been reported. Moreover, mutations have shown incomplete penetrance, and LQTS has variable expressivity even within families. Some individuals with LQTS show no clinical symptoms; however, for approximately 10-15% of individuals diagnosed with LQTS, the first symptom is sudden death. While individuals with LQTS may experience fainting or heart palpitations with exercise, others may experience such
events while at rest or upon auditory stimulation (e.g. GeneDx 2011b).

MFS (OMIM #154700), estimated to have a worldwide prevalence of 1 in 3000-5000, is a connective tissue disorder involving FBN1, a gene marked by considerable pleiotropy (e.g. Pyeritz 2002). Expression is highly variable, but clinical features may include tall stature with disproportionately long limbs, joint hypermobility, ectopia lentis, myopia, mitral valve prolapse, aortic dissection, and aortic root dilation (among others). Genetic testing is considered important to identify pre-symptomatic individuals who could benefit from surveillance (e.g. GeneDx 2012).

Suspected and/or confirmed diagnosis of any of these conditions (HCM, LQTS, or MFS and related disorders) has serious implications for an individual’s future eligibility for participation in competitive athletics (even when the individual is asymptomatic). Many experts and policymakers are convinced by anecdotal evidence suggesting that restriction of physical activity is an appropriate measure to prevent sudden cardiac death (SCD) among individuals with one of these conditions (see, e.g., Maron and Zipes 2005). Empiric data, however, are contradictory as to whether moderate to rigorous physical activity has beneficial or adverse effects on risk of SCD (e.g. Deo and Albert 2012). Additionally, a broad restriction on athletic participation overlooks the variation of the static and dynamic components required of different sports that may confer differential risks of SCD (Vaseghi, Ackerman, and Mandapati 2012).

There is a dearth of empiric data demonstrating that individuals with such genetic variants in genes reported for HCM, LQTS, MFS or related conditions who participate in competitive sports have higher risks of SCD than those individuals with the same genetic variants who refrain from participation in competitive sports. Notably, Hoffman and colleagues (2012) have reported that an FBN1 mutation is not itself a predictor for SCD, and O’Mahony and colleagues (2013) have described the difficulties and limited power of risk stratification algorithms designed to identify those individuals diagnosed with HCM who are at a high risk of SCD.

Preventing sudden cardiac death in athletes is a high priority. As Angelini et al. (2013) noted,

“…[A]t present, it is probably reasonable to assume that 2% to 3% of the general population has cardiovascular conditions…that seem to pose a high risk to competitive sports persons. Considering that the young population constitutes approximately 28% of the total United States population, or about 90 million, the 2% to 3% would correspond to about 2 million people. If we consider only the estimated 1.5 to 10 million “young athletes” in the U.S. (usually defined as
“regular runners” in any given year, 30,000 to 300,000 of them would be expected to carry high-risk cardiovascular conditions (hr-CVCs). Preliminary estimates suggest that 0.1 to 0.6 per 100,000 young people die suddenly of cardiac causes each year, whereas 2 to 7 per 100,000 U.S. athletes die in that manner.”

SCD is the leading cause of death and death during exercise of NCAA student-athletes, with an incidence of 1 in 43,000 student-athletes per year (Harmon et al. 2011). HCM, involved in 36% of cases, is the leading cause of SCD of U.S. athletes (Maron et al. 2009). Sex and racial disparities have been reported by Harmon et al. (2011), noting SCD among male student-athletes was 2.3x more common than among female student-athletes and further noting the incidence of SCD in Black student-athletes was 3x that of White student-athletes. Moreover, SCD rates vary by sport, with SCD most common in basketball, football, swimming, lacrosse, and cross-country. Prevalence of risk factors for SCD has been reported as roughly 3 in 1000 (see Harmon et al. 2011).

Tragic sudden cardiac deaths of youth athletes—such as 16 year old Michigan high school basketball player Wes Leonard (e.g. Moisse 2011), 17 year old Colorado high school rugby player Matthew Hammerdorfer (e.g. Sandell and Dolak 2011), 16 year old California high school swimmer Justin Carr (e.g. Sondheimer 2013), and 23 year old Pennsylvania runner Kyle Johnson (e.g. SCA Foundation 2013, Zimmerman 2013)—grab local and national attention and often prompt calls for stronger protections of youth athletes. Pre-participation screening of athletes has been criticized for being too weak. Lisa Salberg, CEO of the Hypertrophic Cardiomyopathy Association (HCMA), has been a vocal critic of current screening practices stating, “As parents, we encourage our children to participate in athletics and organized sports, however are we doing enough to ensure that they are healthy enough to be playing?” (Hirschhorn 2010). Other criticisms focus on the response to such sudden cardiac arrest emergencies when they do occur: public health advocates call for increased availability of automatic external defibrillators at sporting venues and highlight “success” stories such as that of Davis Nwankwo, a Vanderbilt basketball player who collapsed on the court during practice in 2006 but whose life was saved by his athletic trainer armed with an automatic external defibrillator (e.g. Sayre 2011). The Sudden Cardiac Death of the Young Surveillance and Prevention Project of the Michigan Department of Community Health Genomics Program (See MDCH 2012) has been productive in studying the problem from many angles and has identified 21 action steps in five areas of need to
prevent SCD, including improvement of pre-participation sports screening, training in the use of AEDs and performance of CPR, education/awareness of SCD, and both emergency response and medical examiner protocols (Duquette and Anderson 2012).

Pre-participation educational/awareness and screening programs may provide important opportunities to get the public’s attention on heart health issues. Cascade genetic screening (i.e. a process wherein first degree relatives are screened after a mutation has been identified in a proband) has been touted for its ability to identify carriers who may be asymptomatic or pre-symptomatic and who may benefit from early implementation of surveillance and therapeutic efforts (such as use of implantable defibrillators) (e.g. Ackerman et al. 2011). However, it is important to note the sports implications of identifying genetic variants in asymptomatic or pre-symptomatic individuals who currently have or may in the future have interests in competitive sports. Is identifying such genetic variants a means to ensure player safety or simply a means of facilitating systematic genetic discrimination? While expanding access to genetic risk information is critically important for prevention of SCD, numerous legal and ethical challenges lurk in the ways in which genetic risk information flows among the various actors in the sports context (e.g. from an individual athlete to the athlete’s parents, health care providers, trainers, coaches, administrators, player’s agents, team’s scouts, league officials, media, spectators, boosters, etc.) as well as the way in which decisions are made relying upon that genetic information (ranging from absolute assumption of risks versus involuntary disqualification from participation). Numerous influences suggest that the individual athlete will not be in control of the decision to engage in competitive sports once one or more genetic risk variants is/are discovered – regardless of whether that discovery occurs during participation in genomic medicine and research completely unrelated to sports or during pre-participation screening specifically for sports.

For example, Pennsylvania recently adopted the Sudden Cardiac Arrest Prevention Act (24 P.S. §5331 et seq., P.L. 574, No. 59 §1, effective July 30, 2012). This statute provides that a student-athlete must be removed from play and prevented from returning to play if the individual “is known to have exhibited signs or symptoms of sudden cardiac arrest at any time prior to or following an athletic activity…” (24 P.S. §5333(c)(2)). The statute prohibits the individual’s return to athletic activity “until the student is evaluated and cleared for return to participation in writing by a licensed physician, certified nurse practitioner, or cardiologist” (24 P.S. §5333(c))
While genetic counselors are notably omitted from this list, the statute permits those authorized to provide return-to-play clearances to consult other “licensed or certified medical professionals,” which would include genetic counselors. This is because Pennsylvania is among the states that have passed bills requiring genetic counselors to be a licensed medical profession (63 P.S. § 422.13d, P.L. 576, No. 125 §2, effective February 21, 2012; See also Wagner 2012). The Sudden Cardiac Arrest Prevention Act does not define “signs or symptoms,” and ordinary parsing of the statute’s text indicates “signs” has different meaning from “symptoms.” Otherwise, the terms “signs” and “symptoms” are redundant and “or” is meaningless. Thus, it is possible (if not likely) that those who must comply with the Sudden Cardiac Arrest Prevention Act (i.e. public school officials, their coaches, and those medical practitioners making clearance determinations) will interpret the statute in such a way that the presence of a genetic variant—regardless of the presence or absence of symptoms expressed by the individual—would constitute a “sign” that precludes the individual from participation. A survey of the legislative activity, shown in Table 4, revealed at least 10 states that are presently considering similar legislation to Pennsylvania’s Sudden Cardiac Arrest Prevention Act.

Moreover, the American College of Cardiology (ACC) Bethesda Conference #36 provide specific recommendations regarding eligibility and disqualification of competitive athletes (Maron and Zipes 2005; See also Pelliccia et al. 2008; Maron et al. 2009). Bethesda Conference #36 Guidelines include extensive discussion on HCM, LQTS, MFS and related cardiac conditions. Relevant guidelines are shown in Table 5. These guidelines generally recommend restricting individuals from participation in competitive sports. It is uncertain how the Bethesda Conference #36 Guidelines are intended by the ACC to be applied in cases where the diagnosis of the HCM, LQTS, MFS or related condition is made using a genomic medicine approach available today. While the Bethesda Conference #36 Guidelines note that, at the time the guidelines were drafted, genotype alone did not warrant disqualification from competitive sports, the subsequent biomedical literature and the 2013 ACMG recommendations on reporting incidental findings may contribute to medical professionals making cautious (perhaps overly cautious or paternalistic) medical clearance decisions. Empirical data regarding how medical professionals are currently making sports clearance decisions in light of genomic medicine and research advances and recent legislative and policy activities are not yet available.

The purpose of pre-participation screening is “to provide potential participants with a
determination of medical eligibility for competitive sports that is based on evaluations intended
to identify (or raise suspicion of) clinically relevant, preexisting abnormalities” (Maron et al.
2007). Screening is for “the identification of at-risk athletes and the prophylactic prevention of
cardiac events during sports by selective disqualification” (Maron et al. 2007). Medical
professionals providing eligibility certification and making determinations of disqualification are
expected to follow the American Heart Association (AHA) recommendations for student-athletes
(at both high school and collegiate levels), and failure to comply may expose the medical
professional to malpractice liability for an athlete’s death or injury caused by an abnormality that
would have been discovered had the guidelines been followed (Maron et al. 2007). While the
AHA recommendations require pre-participation screening to consider personal history, family
history, and physical examination (see Table in Maron et al. 2007), they have not required
12-lead electrocardiograms (ECG) or genetic screening (such as those panels offered by GeneDx
for HCM, LQTS, and MFS and related conditions). Genetic screening for HCM was considered
but rejected due to its cost, genetic heterogeneity, and the anticipated frequency of false-negative
results (Maron et al. 2007). Given the nuances of the current biomedical understanding of
various cardiac conditions (including HCM, LQTS, MFS and related conditions), genetic risk
information is informative but far from determinative of a player’s health and corresponding
risks of SCD. Accordingly, it seems unwise to base decisions of athletic eligibility (particularly
eligibility of those individuals who are asymptomatic or pre-symptomatic) on the presence of a
genetic variant alone – even if such genetic variants are covered by the ACMG’s recommended
list for reporting of incidental findings.

Facilitating Player Safety or Genetic Discrimination?

Together, the ACMG recommendations for reporting incidental findings, the Sudden
Cardiac Arrest Prevention Act in Pennsylvania (and similar state bills if adopted), the Bethesda
Conference #36 Guidelines, and general aversions to tort liability risks (e.g. medical malpractice)
will work together in a conservative, paternalistic manner. Undoubtedly such efforts may
promote individual safety; however, it would be inaccurate to characterize these efforts as
promoting player safety. Ultimately the majority of individuals “protected” will not be permitted
to be players at all, since adequate medical clearance paperwork will be hard to come by.

Pre-participation screening practices that serve to disqualify individuals from participation in
sports as a result of family medical history or genetic information when they themselves are asymptomatic is genetic discrimination (specifically, systematic disparate treatment).

Notably, racial disparities exist in sports contexts, including disparate participation in specific sports and in specific positions in team sports (e.g. Graves 2005). Racial disparities exist among athletes as well as among executives/decision-makers. For example, racial minorities represent more than two-thirds (69%) of all NFL players but hold few positions of authority, with racial minorities representing 0% of CEOs/presidents; 3% of majority ownership; < 20% of head coaches or general managers; and < 15% of physicians and head trainers (Lapchick et al. 2012).

The disproportionate participation may be reversed in other sports (e.g. skiing and snowboarding (e.g. Eiss 2011)). Many factors contribute to existing disparities in sports (e.g., sociocultural factors of differential power, wealth, and prestige given to sports, self-selection biases; economic factors influencing access to educational, nutritional, and training resources; environmental factors including in utero exposures; and genetic factors). The existing disparities are an important aspect of the context in which genetic/omic technologies are being integrated in sports training and medicine programs. Understanding this context is essential when evaluating potential challenges arising from this integration of genetic information in sports and the development of “genomic sports medicine.” The genomic revolution has the potential to alleviate or exacerbate racial disparities depending upon how the integration is executed. Enhancing the awareness and understanding of genetic risks and increasing access to health information through pre-participation screening for sports is a means to reach under-served minority populations. However, that health opportunity could translate into employment discrimination, quashing future professional sports employment opportunities via disproportionate selective disqualifications and, in the process, create life-changing psychological, social, professional, and economical impacts within members of those under-served minority populations.

**Sports-Related Genetic/omic Screening**

The integration of genetic/omic technologies in sports contexts is not a hypothetical concept. Various renditions have already been attempted both domestically and internationally for diverse purposes (Wagner 2013). Lawsuits can be strong motivators for the adoption of DNA screening policies. Such efforts promote safety by identifying risks prior to participation, but screening efforts also serve to limit liability exposure of the event organizers, the leagues, the
teams, the schools, etc. Such was the case for the NCAA’s adoption of sickle cell carrier 
screening. The NCAA sickle cell screening policy arose as part of a settlement agreement 
resolving a lawsuit that followed the death of Dale Lloyd II, a 19 year old football player at Rice 
University. The student-athlete died from acute exertional rhabdomyolysis (a complication of 
sickle cell trait) after collapsing on the field upon running a 100-yard sprints (e.g. Zarda 2010). 
The NCAA implemented the screening policy notwithstanding criticism and opposition from the 
American Society of Hematology (ASH), as the ASH favors universally applicable safety 
policies to help athletes regardless of sickle cell carrier status (e.g. Petrochko 2012). The NCAA 
subsequently expanded its screening program beyond Division I athletes to include athletes in 
Divisions II (Hendrickson 2012) and III (Brown 2013).

Genetic screening may be forthcoming for concussion risks (e.g. APOE ε4), if the NFL 
adopts concussion screening as part of settlement agreements for pending lawsuits involving 
more than 4200 players (In Re: National Football League Players’ Concussion Injury Litigation; 
See also Anderson 2013) or if the NCAA reacts to the American Academy of Neurology updated 
guidelines naming APOE as a risk factor for chronic neurobehavioral impairment (Giza et al. 
2013) and expands its screening program beyond sickle cell carrier status. Some have already 
suggested compulsory brain scans and genetic testing for boxers and others have suggested 
banning such sports altogether (e.g. Jordan 1998; Springs 2004; Kelland et al. 2013). At least one 
company that had provided sports-related personal genomics services DTC (Athleticode) has 
repositioned itself to focus specifically on concussion risks.

Genetic screening may also be forthcoming for HCM risks (e.g. MYH7, MYBPC3, and 
TNNT2) as sudden cardiac deaths of seemingly healthy youth (e.g. most recently Kyle Johnson) 
prompt public calls for pre-participation screening. As mentioned earlier, about one-third of 
athletic field deaths in the United States are caused by HCM, an abnormal thickening of the 
ventricular walls of the heart muscle (Maron 2005). Screening for HCM has been advocated not 
to promote safety of those engaged in athletics but, rather, to identify and disqualify individuals 
prior to participation (e.g. Corrado et al. 1998). Distinguishing potentially life-threatening HCM 
from “athlete’s heart,” a non-pathological condition resulting from intense training, is quite 
challenging (E.g. Maron 2005, Cheng 2009; Creswell 2009). Despite potential false negatives, 
genetic testing is the “most definitive way” to distinguish HCM from athlete’s heart (Cheng 
2009). While more than 1000 distinct mutations have been identified, the mutations found within
two genes (MYH7 and MYBPC3, OMIM #160760 and #600958, respectively) collectively account for more than 75-80% of HCM (Ho 2011). In 2010 a jury granted an award of $1.6 million dollars to the parents of Antwoine Key, a 22 year old basketball player for Eastern Connecticut State University who collapsed and died as a result of undiagnosed HCM. The student-athlete had been given clearance to play by five different physicians notwithstanding a heart murmur noted during a pre-participation exam more than three years prior to his collapse (Key v. Abdulah; See also Morlan 2010; Hirschhorn 2010).

**Moving Toward Athlete-Initiated Integrations of Personal Genomics in Sports**

Personal genomics (PGx) services of varying scope and quality (in terms of analysis, return of results, and interpretations) are now available direct-to-consumers. These PGx services include and sometimes focus on traits and conditions relevant to sports (Wagner 2013; Wagner and Royal 2012; Wagner and Royal, unpublished data), allowing individual athletes to access information (a) without coordination with a school, team, or perhaps even parents and (b) specifically outside of the formal and potentially intimidating context of medical care, scientific research, and pre-participation screening processes. Among the ~250 genetic variants implicated in sports-related phenotypes (Rankinen et al. 2010; Bray et al. 2009; Rankinen et al. 2006; Wolfarth et al. 2005; Rankinen et al. 2004; Perusse et al. 2003; Rankinen et al. 2002; Rankinen et al. 2001) are ACTN3, COL5A1, COL12A1, COL1A1, GDF5, ACE, ADRB2, PPARGC1A, MMP3, APOE, MYH7, MYBPC3, TNNT2, DIO1, NOS3, IL6, VEGFR, HIF1, MCT1, EPOR, and SCN5A, all of which have been available as part of one or more DTC sports-related genetic tests (Wagner and Royal 2012). Many of these genetic variants have been characterized as “gene doping targets” (Azzazy et al. 2009) or “candidate genes for sport doping” that will enable “the creation of a superman or superwoman athlete” through “well-placed genetic physiologic tweaks” (Gaffney and Parisotto 2007). However, anthropological geneticists have cautioned that genotype is not the full explanation of “what makes a champion,” as there are many potential confounders, including spurious associations due to population structure or ancestry and the complex and varying effects of gene-environment interactions over an individual’s lifetime (Brutsaert and Parra 2006).

It is evident that the sports-related sector of the larger PGx industry has considerable potential for diversity in terms of phenotypes of interest and genetic loci assayed. Previous
research identified the companies in the sports-related PGx industry and analyzed information
provided online to prospective consumers (Wagner and Royal 2012). An empiric investigation
involving participant observation and the purchase of four sports-related DNA tests in 2011
(Wagner and Royal, unpublished data) revealed that there is, in fact, considerable diversity in
offerings and that there simply is no “typical” or “standard” sports-related DTC panel for the
PGx industry (See Table 6). PGx offerings for genetic information related to power or strength
have focused on $ACTN3$ (rs1815739, OMIM #102574), $IL6$ (rs1800795, OMIM #147620), and
$DIO1$ (rs11206244 and rs12095080, OMIM #147892). For endurance, PG offerings have focused
on $NOS3$ (rs2070744 and rs1799983, OMIM #163729), $HIF1A$ (rs11549465, OMIM #603348),
$MCT1$ (rs1049434, OMIM #600682), $VGFR$ (OMIM #191306), and $EPOR$ (rs121918116,
OMIM #133171). PGx offerings for soft tissue injury risks have focused on $MMP3$ (rs679620,
rs591058, rs650108, OMIM #185250), $COL5A1$ (rs12722, OMIM #120215), $COL12A1$
rs970547, OMIM #120320), $COL1A1$ (rs1800012, OMIM #120150), and $GDF5$ (rs143383,
OMIM #601146). For cardiac risks, PG offerings have focused on $MYH7$ (OMIM #160760),
$MYBPC3$ (OMIM #600958), and $SCN5A$ (rs7626962, OMIM #600163). PGx offerings have
even included concussion risks, focusing on APOE (OMIM #107741). Upon closer examination,
it is apparent that AIBiotech has provided access to a number of genes on the ACMG’s
recommended incidental findings report: AIBiotech has provided exome sequencing of $MYH7$,
$MYBPC3$, and $TNNT2$ (three of the genes related to HCM risks) and testing of $SCN5A$ (a gene on
the ACMG’s list of recommended reporting for LQTS and related acquired arrhythmias).
$SCN5A$, a cardiac sodium channel gene with a number of common polymorphisms (OMIM
#600163) (Cheng 2011), contains a Y1002 variant (S1103Y, rs7626962) that is rare in European
Americans (Smith et al. 2011) but reported at allele frequencies ~13.2% in African Americans
(Slawski et al. 2002). This polymorphism reportedly causes a “small but inherent and chronic
risk of acquired arrhythmia” (Slawski et al. 2002).

While 23andMe is not focused on providing a sports-related service, its PGx analysis
does incorporate much of the information athletes could seek elsewhere. 23andMe provides
reports on muscle performance, response to diet, response to exercise, pain sensitivity, asthma,
sickle cell carrier status, heart rhythm disorders, and APOE4 status (though not reported for
concussion risk (see BethannH 2013)). The 23andMe’s latest platform (version 3) has
considerable coverage of the recommended ACMG list shown previously in Table 3. Browsing
raw data in 23andMe for the first three genes of each condition listed in Table 3, the PGx service includes 33 SNPs in MYBPC3, 52 SNPs in MYH7, and 30 SNPs in TNNT2 (three genes on ACMG’s list for HCM); 271 SNPs in KCNQ1, 50 SNPs in KCNH2, and 116 SNPs in SCN5A (three genes on ACMG’s list for LQTS and related arrhythmias); and 139 SNPs in FBN1, 26 SNPs in TGFBR1, and 75 SNPs in TGFBR2 (three genes on ACMG’s list for MFS and related disorders). The consumer’s or user’s ability to download the raw data from 23andMe for subsequent independent analysis and interpretation makes it attractive for individuals whose motivations may include sports-related purposes.

Collegiate sports medicine and athletic programs are beginning to incorporate PGx as well. One example is Dr. Stuart Kim’s work to integrate PGx for injury risk prevention at Stanford University (see https://sportsgenetics.stanford.edu/). The Stanford pilot program focuses on secondary analysis and interpretation of 23andMe raw data files (version 3 platform) to assess risks for stress fractures, ACL ruptures, Achilles tendinopathy, disc degeneration, hemoglobin count, vitamin and mineral deficiencies, and osteoarthritis as well as sickle cell carrier status. Participants upload their 23andMe raw data to the program’s website and Dr. Kim and his colleagues perform secondary analysis of the data. The program involves one-hour consultations to discuss the results, and the idea is that athletes could modify their training programs, take nutritional supplements (e.g. Vitamin D), and obtain additional medical services to prevent disruptions to their athletic seasons due to injury. At least 15 elite athletes from the Stanford Triathlon Club have participated thus far. This pilot program is expected to expand to include the Varsity cross-country teams at Stanford and the University of California Los Angeles before being proposed for adoption by the Pac-12 Conference at large (Personal communication with Dr. Stuart Kim; March 15, 2013) and the program has also initiated recruitment of endurance athletes in the San Francisco bay area.

Recognizing the Vulnerabilities of Student-Athletes

Individuals with extraordinary athletic abilities are rarely thought of or described as “vulnerable” (but see Davis 1998). Nonetheless, when considering the potential and probable applications of PGx in sports contexts, a number of characteristics suggest the vulnerability (See, e.g., Beauchamp and Childress 2009) of student-athletes. To ensure (1) respect for autonomy of the student-athletes, (2) optimization of the risks and benefits, and (3) promotion of justice
among student-athletes, recognition of these vulnerabilities suggests heightened care be exercised when developing a program incorporating PGx technologies. These vulnerabilities of student-athletes highlight potential reasons why a DTC market will and should continue to exist (and why best practices should be promoted within the broader PGx industry), as individuals interested in sports should have a means to access their own PGx information without other actors (i.e. parents, coaches, league officials, medical providers, etc.) automatically and/or simultaneously gaining unfettered access to those data.

First, student-athletes are often under the age of majority (i.e. 18 or 21 years of age), which effectively limits the individuals’ ability to enter into contracts or provide consent independently and thereby perpetuates a state of dependency upon parents or guardians. Regulatory protections for participation in research include the requirement that researchers obtain not only informed assent from minors but corresponding informed consent from the minors’ parents or guardians. Considerable deference is given to parents in the U.S. to make decisions in the “best interest of the child” (See, e.g., Troxel v. Granville). Nonetheless, parents may hold extreme perspectives regarding PGx and/or sports that could impinge on the student-athletes’ ability to effectuate their needs and interests in this context. For example, parents espousing genetic determinism could alternatively deny or compel their children to obtain PGx information for sports purposes. Economic dependency of student-athletes further exacerbates the potential compromise of autonomous decision-making by student-athletes who are considering the use of PGx in sports contexts.

Coercive pressures to participate in any activity perceived to provide a competitive edge along with the intensely competitive personalities of student-athletes create vulnerabilities for student-athletes as well. While coercive pressures of the business of sports should be acknowledged when present, they cannot be assumed a priori as undue influences that negate or preclude voluntary consent from student-athletes. Red flags raised by existing coercive pressures, however, suggest that recruitment procedures include education and outreach efforts to explain clearly the details of the program and further suggest that a reasonable waiting period be provided to ensure that decisions to participate are made deliberately and upon disclosure of adequate information.

A third characteristic of vulnerability is the precarious status that student-athletes hold under the Genetic Information Nondiscrimination Act (GINA). Title II of GINA prohibits
employers and labor organizations from requesting or using genetic information in employment decisions. As was previously examined elsewhere, sports employment is not exempted from GINA Title II’s prohibition on using genetic information to limit, classify, segregate employees (i.e. players), and employers enjoy no defense for use of genetic information as a “bona fide occupational qualification” (Wagner 2013). GINA coverage, however, does not clearly situate student-athletes under the umbrella of a protected class. Rather, GINA protections extend only to former employees, current employees, and prospective employees. Current amateur rules and legal fictions combine forces in ways that undermine the general labor and genetic nondiscrimination protections of student-athletes. In exchange for the opportunity for a position on the team, the privilege to wear the uniform, and the benefits of education and scholarships, student-athletes transfer any monetary benefits of their hard-earned labors to others (i.e. they waive earnings) and must refrain from gainful employment elsewhere (i.e. they agree to broad-sweeping non-compete covenants). Notwithstanding this exchange of ongoing benefits and obligations, student-athletes are denied status as school “employees” (See, e.g., Maisel 2011; McCormick and McCormick 2006; See also Branch 2011). While numerous arguments can be made to extend GINA status as “current employees” (with schools as the covered entities) and as “prospective employees” (with professional teams as the covered entities) to student-athletes for purposes of GINA, this uncertain status exposes student-athletes to genetic discrimination as a foreseeable consequence (a) of participation (or non-participation) in sports programs integrating PGx (such as the Stanford program) and (b) of the application of genetic technologies in pre-participation screening programs.

Finally, student-athletes are often treated with celebrity status (locally, regionally, nationally, and internationally), creating privacy concerns. Privacy rights in the U.S. are protected contextually (not with one broad-sweeping statute), and are balanced with other interests (such as First Amendment freedoms of speech and association). While one need not “live the life of a recluse” to enjoy privacy rights (Maxey 1937), celebrity status broadens that which is newsworthy and is sometimes considered a waiver of some privacy rights (e.g. Hull v. Curtis Publishing Co). The integration of genetic screening programs or use of PGx in sports could undermine the individual’s genetic privacy interests and expose the individual to a number of future risks, including discrimination (See, e.g. Quick 2012).
Conclusions

While some may claim the limited scope of the ACMG recommendations (i.e. WGS/WES in clinical settings) indicates that very few individuals would fit the problematic scenario outlined here, that assumption is not supported by any data. Moreover, that assumption fails to consider that those performing WGS/WES in non-clinical settings may, too, look to the ACMG’s recommendations for guidance on what the professional standard of conduct should be. The possibility of discovering “incidental findings” in the ACMG’s list of genes with WGS/WES of normal, unaffected, or asymptomatic individuals is not negligible. Healthy individuals, as a result, might be precluded from participation in sports unfairly as a result of the conservative influences of the Sudden Cardiac Arrest Prevention Act in Pennsylvania (and similar state statutes if adopted), the Bethesda Conference #36 Guidelines, and the broader medical profession’s aversion to tort liability risks. Even when medical clearances to play are provided by medical professionals, genetic illiterate or genetic deterministic parents may serve as distinct barriers for sports participation. Updated guidelines clarifying how the ACMG’s recommended list of reporting incidental findings should be reconciled with these conservative forces causing medical professionals to err on the side of caution in sports contexts (i.e. disqualification or restriction from athletic activity). It is possible that surveillance – not disqualification or restriction from participation in competitive sports – is an appropriate measure for asymptomatic individuals who happen to carry a variant in one of the genes noted in Table 3. Such an approach acknowledges the public health interests in preventing sudden cardiac death but balances those interests in a way that respects the individuals’ personal interests in assuming the risks and playing competitive sports notwithstanding the presence of a genetic risk variant. Individuals will vary in their reactions to learning personal genetic information. Within reason, those individual reactions and preferences for risk assumption should be respected.

When integrating genetic technologies into sports settings, it is absolutely essential that the intended purposes and unintended consequences are carefully considered during program development and that these are subsequently re-evaluated on a recurring basis throughout implementation. While official guidelines for genomic athletic programs or genomic sports medicine programs are not yet available, a few preliminary suggestions may be articulated here. First, the goals and purposes of the integration of PGx into any sports medicine or athletic program must be clearly defined. Identifying the distinct motivations for and interests in PGx in
any sports system (such as the individual athletes seeking empowerment through more personalized pre- and re-habilitation strategies, the coaching personnel seeking information with which to consider talent and injury risks when distributing limited athletic scholarships, and the trainers and medical personnel seeking improved care strategies) is key to preparing the system to avoid unintended consequences and facilitate achievement of its intended purposes. Any integration at the collegiate level will have downstream effects if/when athletes attempt to transition to the professional sports level. Care must be exercised to avoid disparate treatment and impacts that could exacerbate existing inequities (including racial disparities). Second, transparency of the authorized flow of information is integral to a successful program. The extent to which PGx information is accessible and/or shared within the personnel structure of a program affects student-athletes’ rights and interests. Prior to any implementation of PGx in sports medicine and athletic programs, designers must make deliberate decisions about the intended direction and volume of the informational flow for the system. Transparency promotes not only compliance with HIPAA/HITECH data security and privacy requirements but also respect for contextual integrity. Third, “terms of use” must be established for all potential decision-makers in the program. Distinct categories of use should be clearly articulated, such as (1) required, (2) recommended, (3) authorized/permissive, and (4) prohibited uses. Terms of use should reflect specific roles of trainers, coaches, and administrators within such programs and also specific contexts in which PGx information might be valuable. Enforcement mechanisms should be articulated. These enforcement mechanisms could incorporate disciplinary standards (such as loss of authorization/access) and could incorporate provisions for liquidated damages for the individual victims of the violations (carefully structured such that any payout avoids jeopardizing the athlete’s “amateur” status). Fourth, such programs should adopt policies and procedures to minimize opportunities for the voluntariness of a decision to participate to become compromised. The existence of coercive pressures alone (from peers, parents, coaches, etc) does not preclude voluntary participation in a PGx sports medicine or athletic program; however, such pressures do present challenges for obtaining voluntary assent/consent. Education of athletes, trainers, coaches, administrators, and media relations for each program could alleviate challenges by establishing reasonable expectations and behavioral norms. Finally, program administrators should engage players’ associations and advocates for student-athletes. Each stage (design, implementation, and operations) of programs that integrate PGx would benefit from periodic
review by advocates for the athletes and from regular feedback from players’ associations regarding issues emerging with athletes’ transition to the professional sports level.

While promoting player safety is a laudable goal, facilitating unfettered genetic discrimination of asymptomatic athletes is an unfortunate but likely outcome under present policy conditions. Given disparate rates of participation of individuals of racial minorities in particular mainstream sports (e.g. basketball, football, baseball, soccer, etc), there is a valuable opportunity to provide access to education and genetic risk information (about sudden cardiac death and other serious medical conditions) to individuals and their families (and by extension their communities). This opportunity also suggests there is ample room for disparate discriminatory impacts if decisions based on that screening information (e.g. disqualification from participation) are mandated in fact or in practice. Moreover, the adoption of “fair competition” policies is precisely to restrict normal variation in athletic abilities. The co-existence of the Olympic Games, Paralympics, and Special Olympic Games is an obvious example, though sex segregation, age levels, and weight classes are demonstrative as well.

Policies to disqualify, limit, or otherwise classify athletes on the basis of carrying a genetic risk variant is essentially the beginning of genetic segregation in sports. Such policies – even when attempting to serve public health goals – reify public notions of genetic determinism. Moreover, because the distribution of genetic diversity today is a function of our demographic and evolutionary past, such policies could disproportionately distribute risks and benefits of the integration of PGx in sports.

Finally, the integration of PGx in sports must be considered as part of a broader data-rich movement. The “Information Age” has enabled increasingly personalized diet and exercise regimes, shaped by personal data generated on mobile devices that monitor nutritional intake, activity levels, and sleep patterns and subsequently shared online with family, friends, teammates, and strangers. While serious athletes are likely early-adopters of PGx (as high rewards may be gained from small improvements in performance), casual athletes may be quick to follow. The public’s reception of PGx in sports medicine and athletic programs will be dependent upon genetic literacy and will be influenced (positively or negatively) by the program’s design (e.g. the care with which biopsychosocial, legal, and ethical challenges are anticipated and successfully managed). Waiting to educate individuals about genetic information until they are in a clinic as patients (or parents of patients), in a laboratory as research
participants, or in an attorney’s office or administrative setting facing specific, life-altering
decisions (from end-of-life care in light of APOE4 Alzheimer disease risks to participation in
competitive sports in light of sudden cardiac arrest risks) is simply too late. Genomic sports
medicine and PGx in athletic settings provide an extraordinary opportunity to improve awareness
of sudden cardiac death and improve genetic literacy generally. The Ad Council has provided
important and effective public service announcements for generations (e.g. the Smokey the Bear
campaign in 1944 helping kids prevent forest fires; “A mind is a terrible thing to waste”
campaign supporting the United Negro College Fund in 1972; McGruff the Crime Dog taking a
bite out of crime in 1978; and the Crash-Test dummies encouraging kids to buckle safety-belts in
1985) (Ad Council 2013a). In 2005 the Ad Council launched a Coalition for Healthy Children to
fight childhood obesity using campaigns geared toward kids and parents, including “Be a Player:
Get up and Play an Hour a Day” and “Eat well. Play hard. Make it balance” campaigns (Ad
Council 2013b). Similarly, numerous league-affiliated initiatives (e.g. NFL’s “Play 60” or “NBA
Cares”) are designed to “give back” to communities and improve health, fitness, and quality of
life of kids. Pilot campaigns and empiric data are needed to explore whether great strides could
be made in improving genetic literacy via exposure to the topic via the public’s enthusiastic
interest in sports. Whether access to PGx information will empower athletes or oppress them is
not a predetermined outcome. To enable the former and prevent the latter requires active policy
development rather than passive observation.

Acknowledgements
Preparation of this article was supported in part by Grant No. K99HG006446-02 and by Grant
No. P50HG004487-05 from the National Human Genome Research Institute (NHGRI). Purchase
of the four underlying sports-related DNA tests discussed was possible in 2011 thanks to funding
support from Dr. Charmaine Royal at the Duke Institute for Genome Sciences & Policy at Duke
University. The content of this article is solely the author’s responsibility and may not represent
the official views of the NHGRI or the University of Pennsylvania. The author is grateful to
Reed Pyeritz for his generous mentoring support and to Shana Merrill, Debra Duquette, Jessica
Mozersky, and Heather Norton for constructive dialogue on this research topic.

References
Ackerman MJ, Prior SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, and Zipes DP. HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. Europace. 2011; 13(8): 1077-1109. doi: 10.1093/europace/eur245

Ad Council. The Story of the Ad Council. 2013a. Available at http://www.adcouncil.org/About-Us/The-Story-of-the-Ad-Council Last accessed June 18, 2013.

Ad Council. Coalition for Healthy Children: Combating Childhood Obesity. 2013b. Available at http://www.healthychildrencoalition.org/messages.html#kids Last accessed June 18, 2013.

American College of Medical Genetics and Genomics. Incidental Findings in Clinical Genomics: A Clarification. May 2, 2013. Available at www.acmg.net/docs/Incidental_Findings_in_Clinical_genomics_A_Clarification.pdf Last accessed June 9, 2013.

Anderson PD. NFL Concussion Litigation. Available at www.nflconcussionlitigation.com Last accessed June 11, 2013.

Angelini P, Vidovich MI, Lawless CE, Elayda MA, Lopez JA, Wolf D, Willerson JT. Preventing Sudden Cardiac Death in Athletes: In search of Evidence-Based, Cost-Effective Screening. Texas Heart Institute Journal 2013; 40(2): 148-55.

Azzazy HME, Mansour MMH, and Christenson RH. Gene doping: Of mice and men. Clinical Biochemistry. 2009; 42: 435-441.

Beauchamp TL and Childress JF. 2009. Principles of biomedical ethics. 6th ed. New York: Oxford University Press.

BethannH. Brain injury, mental decline, and the APOE gene. 23andMe Blog. April 4, 2013.
Available at http://blog.23andme.com/health-traits/brain-injury-mental-decline-and-the-apoe-gene/ Last accessed June 12, 2013.

Branch T. The Shame of College Sports. The Atlantic. September 7, 2011. Available at http://www.theatlantic.com/magazine/archive/2011/10/the-shame-of-college-sports/308643/ Last accessed June 11, 2013.

Bray, MS et al. The Human Gene Map for Performance and Health-Related Fitness Phenotypes: The 2006–2007 Update. Medicine & Science in Sports Exercise. 2009; 41(1): 34–72. DOI: 10.1249/MSS.0b013e3181844179

Brown G. DIII approves sickle cell measure. January 19, 2013. Available at http://www.ncaa.org/wps/wcm/connect/public/NCAA/Resources/Latest+News/2013/January/DII+approves+sickle+cell+trait+confirmation+requirement Last accessed June 11, 2013.

Brutsaert TD and Parra EJ. What makes a champion? Explaining variation in human athletic performance. Respiratory Physiology & Neurobiology. 2006; 151(2-3):109-123.

Cheng TO. Hypertrophic cardiomyopathy vs athlete's heart. International Journal of Cardiology. 2009; 131: 151-155.

Cheng J et al. The common African American polymorphism SCN5A-S1003Y interacts with SCN5A-R680H to increase late Na current. Physiol Genomics 2011; 43(9): 461-6.

Corrado D, Basso C, Schiavon M, and Thiene G. Screening for Hypertrophic Cardiomyopathy in Young Athletes. New England Journal of Medicine. 1998; 339: 364-369. DOI: 10.1056/NEJM199808063390602

Creswell LL. Hypertrophic Cardiomyopathy (HCM). The Athlete’s Heart Blog 2009. Available Online: http://athletesheart.blogspot.com/2009/10/hypertrophic-cardiomyopathy-hcm.html Last
Davis DS. Medical Research with College Athletes: Some Ethical Issues. The Hastings Center Report. 1998; 20(4): 10-11.

Deo R and Albert CM. Epidemiology and Genetics of Sudden Cardiac Death. Circulation. 2012; 125:620-637. doi: 10.1161/CIRCULATIONAHA.111.023838

Duquette D and Anderson B. Can Sudden Cardiac Death of the Young be Prevented? CDC Genomics and Health Impact Blog. March 1, 2012. Available at http://blogs.cdc.gov/genomics/2012/03/01/cardiac-death-of-the-young/ Last accessed June 9, 2013.

Eiss M. Team USA Ski and Snowboard 2010: Disparities of Racial and Class Representation. University of Colorado Boulder Honors Journal. 2011. Available at http://www.colorado.edu/honorsjournal/content/team-usa-ski-and-snowboard-2010-disparities-racial-and-class-representation Last accessed June 11, 2013.

Friedman Ross L, Saal HM, David KL, Anderson RR, American Academy of Pediatrics, and American College of Medical Genetics and Genomics. Technical Report: ethical and policy issues in genetic testing and screening of children. Genetics in Medicine. 2013; 15(3): 234-245.

Gaffney GR and Parisotto R. Gene Doping: A Review of Performance-Enhancing Genetics. Pediatric Clinics of North America. 2007; 54:807-822

GeneDx. Test Information Sheet: Cardiology Genetics: Hypertrophic Cardiomyopathy (HCM) Panel. Revised February 2011. Available at http://www.genedx.com/wp-content/uploads/crm_docs/info_sheet_hcm.pdf Last accessed June 9, 2013.

GeneDx. Test Information Sheet: Cardiology Genetics: Long QT Syndrome (LQTS) Panel.
Revised Apr 2011. Available at
http://www.genedx.com/wp-content/uploads/crm_docs/info_sheet_lqt.pdf Last accessed June 9, 2013.

GeneDx. Test Information Sheet: Cardiology Genetics: Marfan syndrome/ Thoracic Aortic Aneurysm and Dissection (TAAD) and Related Disorders. Revised July 2012. Available at
http://www.genedx.com/wp-content/uploads/crm_docs/Info_sheet_marfan_TAAD.pdf Last accessed June 9, 2013.

Genetic Information Nondiscrimination Act of 2008, P. L. 110-233, 122 Stat 881, codified at 42 USC 2000ff et seq.

Giza CC, Kutcher JS, Ashwal S, Barth J, Getchius TSD, Gioia GA, Gronseth GS, Guskiewicz K, Mandel S, Manley G, McKeag DB Thurman DJ, Zafonte R. Summary of evidence-based guideline update: Evaluation and management of concussion in Sports: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013; 80(24): 2250-2257). Published online before print on March 18, 2013. DOI 10.1212/WNL.0b013e31828d57dd

Graves J. The Race Myth. Why we Pretend Race Exists in America. Plume: New York. 2005; Pp. 137-165. ISBN: 0452286581

Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, McGuire A, Nussbaum RL, O’Daniel JM, Ormond KE, Rehm HL, Watson MS, Williams MS, and Biesecker LG. ACMG Recommendations for Reporting of Incidental Findings in Clinical Exome and Genome Sequencing. March 22, 2013. Available at
http://www.acmg.net/docs/ACMG_Releases_Recommendations_on_Incidental_Findings_in_Clinical_Exome_and_Genome_Sequencing.pdf Last accessed June 9, 2013.

Harmon KG, Asif IM, Klossner D, and Drezner JA. Incidence of Sudden Cardiac Death in National Collegiate Athletic Association Athletes. Circulation. 2011; 123: 1594-1600. Doi:
Heger M. Debate heats up on ACMG’s Incidental Findings Recommendations. Genome Web May 22, 2013. Available at http://www.genomeweb.com/clinical-genomics/debate-heats-acmgs-incidental-findings-recommendations Last accessed June 9, 2013.

Hendrickson B. DII moves toward start of testing for sickle cell trait. January 30, 2012. http://www.ncaa.org/wps/wcm/connect/public/NCAA/Resources/Latest+News/2012/January/DII+moves+toward+start+of+testing+for+sickle+cell+trait Last accessed June 11, 2013.

Hirschhorn W. The Hypertrophic Cardiomyopathy Association Weighs In on the Antwoine Key Verdict: The Cautionary Tale of a Big Heart. HCMA. February 4, 2010. Available at http://www.4hcm.org/hcma-outreach-events/press-releases/244094-the-hypertrophic-cardiomyopathy-association-weighs-in-on-the-antwoine-key-verdict-the-cautionary-tale-of-a-big-heart.html Last accessed June 9, 2013.

Ho CY. New paradigms in hypertrophic cardiomyopathy: Insights from genetics. Progress in Pediatric Cardiology. 2011; 31(2): 93-98.

Hoffman BA, Rybczynski M, Rostock T, Servatius H, Drewitz I, Steven D, Aydin A, Sheikhzadeh S, Darko V, von Kodolitsch Y, and Willems S. Prospective risk stratification of sudden cardiac death in Marfan’s syndrome. International Journal of Cardiology. 2012; xxx-xxx. doi:10.1016/j.ijcard.2012.06.036

Hull v. Curtis Pub. Co., 182 Pa.Super. 86, 125 A.2d 644 (1956)

In Re: National Football League Players’ Concussion Injury Litigation, Eastern District of Pennsylvania, Docket No. 2:12-md-02323-AB.

Jordan BD. Genetic Susceptibility to Brain Injury in Sports. Physician and Sports Medicine.
Kelland K. Should science on brain injury inspire a ban on boxing. Yahoo Sports. March 21, 2013. Available at
http://sports.yahoo.com/news/science-brain-injury-inspire-ban-023210010--nfl.html Last accessed June 11, 2013.

Key v. Abdulah, 2010 WL 2216004 (Slip Verdict, March 26, 2010)

Lapchick R, Costa P, Sherrod T, and Anjorin R. The 2012 Racial and Gender Report Card: National Football League. UCF Institute for Diversity and Ethics in Sport. September 13, 2012. Available at: http://dl.dropboxusercontent.com/u/11322904/2012%20NFL%20RGRC.pdf. Last accessed 5/26/13

Maron BJ. Distinguishing hypertrophic cardiomyopathy from athlete’s heart: a clinical problem of increasing magnitude and significance. Heart. 2005; 91(11): 1380-1382.

Maron BJ and Zipes DP. 36th Bethesda Conference: Eligibility Recommendations for Competitive Athletes With Cardiovascular Abnormalities. Journal of the American College of Cardiology. 2005; 45(8): 1312- doi:10.1016/j.jacc.2005.02.004

Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, Dimeff R, Douglas PS, Glover DW, Hutter Jr. WOM, Krauss MD, Maron MS, Mitten MJ, Roberts WO, Puffer JC. Recommendations and Considerations Related to Preparticipation Screening for Cardiovascular Abnormalities in Competitive Athletes: 2007 Update: A Scientific Statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation. Circulation. 2007; 115; 1643-1655.

Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009; 119(8): 1085-92.
Maron BJ, Maron MS, Semsarian C. Genetics of Hypertrophic Cardiomyopathy after 20 Years. Journal of the American College of Cardiology. 2012; 60(8): 705-715.

http://dx.doi.org/10.1016/j.jacc.2012.02.068

Maxey J (concurring opinion). Waring v. WDAS Broadcasting Station, 327 Pa. 433, 463, 194 A. 631, 645 (1937).

McCormick RA and McCormick AC. The Myth of Student-Athletes: The College Athlete as an Employee. Washington Law Review. 2006; 81:71-157. Available at http://digital.law.washington.edu/dspace-law/bitstream/handle/1773.1/262/81washlrev71.pdf

Medical Practice Act of 1985, 63 P.S. § 422.1 et seq., as amended by 63 P.S. § 422.13d, P.L. 576, No. 125 §2, effective February 21, 2012.

Michigan Department of Community Health (MDCH). Too Young to Die: an update on the impact of sudden cardiac death of the young in Michigan, 1999-2011. June 19, 2012. Available at http://www.michigan.gov/documents/mdch/6­18_SCDY_Report_FINAL_June2012_389619_7.pdf Last accessed June 9, 2013.

Meisel I. Paying players might create havoc. ESPN.com July 15, 2011. Available at http://espn.go.com/college-sports/story/_/id/6768571/legal-issues-arise-paying-student-athletes Last accessed June 11, 2013.

Moisse K. Wes Leonard: Michigan High School Basketball Star Dies After Game-Winning Shot ABC News. March 4, 2011. Available at http://abcnews.go.com/Health/HeartDisease/high-school-basketball-star-dies-court/story?id=13055595#.UbSdcOtAuJM Last accessed June 9, 2013.

Morlan K. Family and Estate of Antwoine Key v. Dr. Dorina R. Abdullah. Moore Law Lexpedia (blog). (March 27, 2010). Available at http://www.morelaw.com/verdicts/case.asp?n=&s=MA&d=43384 Last accessed June 13, 2013.
O’Mahony C, Tome-Esteban M, Lambiase PD, Pantazis A, Dickie S, McKenna WJ, and Elliott PM. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart. 2013; 99:534-541. Doi:10.1136/heartjnl-2012-303271

Online Mendelian Inheritance in Man (OMIM). [www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM](http://www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM)

Pérusse L, et al. The human gene map for performance and health-related fitness phenotypes: the 2002 update. Medicine & Science in Sports & Exercise. 2003; 35(8):1248-64.

Petrochko C. Docs Contradict NCAA on Sickle Cell Trait Tests. MedPage Today. January 27, 2012. Available at [http://www.medpagetoday.com/Genetics/GeneticTesting/30885](http://www.medpagetoday.com/Genetics/GeneticTesting/30885) Last accessed June 11, 2013.

Pyeritz RE. Marfan syndrome and other disorders of fibrillin. In: Rimoin DL, Conner JM, Pyeritz RE, Korf B, editors. Principles and Practice of Medical Genetics. 4th edition. Edinburgh: Churchill Livingstone, 2002:3977–4020.

Quick H. Privacy for safety: the NCAA sickle-cell trait testing policy and the potential for future discrimination. Iowa Law Review. 2012; 97: 665-691.

Rankinen, T et al. Advances in Exercise, Fitness, and Performance Genomics. Medicine & Science in Sports & Exercise. 2010; 42(5): 835–846. DOI: 10.1249/MSS.0b013e3181d86cec

Rankinen T et al. The human gene map for performance and health-related fitness phenotypes: the 2005 update. Medicine & Science in Sports & Exercise. 2006; 38(11): 1863-88

Rankinen T et al. The human gene map for performance and health-related fitness phenotypes: the 2003 update. Medicine & Science in Sports & Exercise. 2004; 36(9): 1451-69.
Rankinen T. et al. The human gene map for performance and health-related fitness phenotypes: the 2001 update. Medicine & Science in Sports & Exercise. 2002; 34(8): 1219-33.

Rankinen T. et al. The human gene map for performance and health-related fitness phenotypes. Medicine & Science in Sports & Exercise. 2001; 33(6): 855-67.

Sandell C and Dolak K. Colorado Teen Dies After Hit on Rugby Field. ABC News. March 6, 2011. Available at http://abcnews.go.com/US/colorado-teen-dies-hit-rugby-field/story?id=13071608#.UbSeDoTaucJM Last accessed June 9, 2013.

Sayre C. Saving athletes from cardiac arrest. Time. March 7, 2007. Available at http://www.time.com/time/health/article/0,8599,1618058,00.html Last accessed June 9, 2013.

Smith JG et al. Genome-Wide Association Studies of the PR Interval in African Americans. PLoS Genetics 2011, 7(2), e1001304.

Sondheimer E. Harvard-Westlake students mourn sudden death of 16-year-old swimmer. LA Times Local Blogs: LA Now. February 25, 2013. Available at http://latimesblogs.latimes.com/lanow/2013/02/harvard-westlake-swimmer-justin-carr-dies.html Last accessed June 9, 2013.

Saplowski I et al. 2002. Variant of SCN5A Sodium Channel Implicated in Risk of Cardiac Arrhythmia. Science 2002, 297, 1333.

Spriggs M. Compulsory brain scans and genetic tests for boxers – or should boxing be banned? Journal of Medical Ethics. 2004; 30: 515-516. DOI: 10.1136/jme.2003.003541

Sudden Cardiac Arrest Foundation. Runner, 23, Dies of Sudden Cardiac Arrest During Pittsburgh Marathon. May 6, 2013. Available at http://www.sca-aware.org/sca-news/runner-23-dies-of-sudden-cardiac-arrest-during-pittsburgh-marathon
Sudden Cardiac Arrest Prevention Act, 24 P.S. §5331 et seq., P.L. 574, No. 59 §1, effective July 30, 2012.

Troxel v. Granville, 530 U.S. 57, 65; 120 S Ct 2054, 2060 (2000)

Vaseghi M, Ackerman MJ, and Mandapati R. Restricting Sports for Athletes With Heart Disease: Are We Saving Lives, Avoiding Lawsuits, or Just Promoting Obesity and Sedentary Living? Pediatric Cardiology. 2012; 33:407–416. DOI 10.1007/s00246-012-0170-6

Wagner JK and Royal CD. “Field of Genes: An Investigation of Sports-Related Genetic Testing.” Journal of Personalized Medicine. 2012; 2(3):119-137. doi:10.3390/jpm2030119

Wagner JK. Pennsylvania joins growing list of States to License Genetic Counselors. Genomics Law Report. February 6, 2012. Available at http://www.genomicslawreport.com/index.php/2012/02/06/pennsylvania-joins-growing-list-of-states-to-license-genetic-counselors/ Last accessed June 9, 2013.

Wagner JK. Sidelining GINA: The Impact of Personal Genomics and Collective Bargaining in Professional Sports. Virginia Sports and Entertainment Law Journal. 2013; 12:81-125.

Wolfarth B. et al. The human gene map for performance and health-related fitness phenotypes: the 2004 update. Medicine & Science in Sports & Exercise. 2005; 37(6):881-903.

Zarda B. Lawsuit prompts NCAA to screen athletes for sickle cell. USA Today. July 2, 2010. Available at http://usatoday30.usatoday.com/sports/college/2010-06-30-sickle-cell-ncaa-cover_N.htm Last accessed June 11, 2013.

Zimmerman A. No sign of problem before runner's death in Pittsburgh's half marathon.
Pittsburgh Post Gazette. May 7, 2013. Available at
http://www.post-gazette.com/stories/local/region/23-year-old-man-dies-running-pittsburghs-half-marathon-686404/ Last accessed June 9, 2013.
Table 1 (on next page)

AAP and ACMG positions on genetic testing and screening of youth
### Table. AAP and ACMG positions on genetic testing and screening of youth

| Category                        | Position                                                                                                    |
|---------------------------------|-------------------------------------------------------------------------------------------------------------|
| School-based screening or testing| “The AAP and the ACMG do not support school-based genetic screening or testing because the school setting raises concerns about whether the uptake is informed and voluntary, whether privacy and confidentiality are maintained, and whether appropriate genetic counseling is provided before and after testing.” (p. 237) |
| Carrier screening               | “The AAP and ACMG do not support routine carrier testing or screening for recessive conditions when carrier status has no medical relevance during minority.” (p. 236) |
| Direct-to-Consumer testing      | “The AAP and the ACMG strongly discourage the use of DTC and home-kit genetic testing of children.” (p. 241) |
Table 2 (on next page)

AAP and ACMG positions on youth access to testing and results
Table 2. AAP and ACMG positions on youth access to testing and results

| Access to testing                                                                 |
|----------------------------------------------------------------------------------|
| “If an adolescent is not interested in testing, and the clinical benefits of     |
| knowing will not be relevant for years to decades, the adolescent’s dissent    |
| should be final.” (p.238)                                                        |
| “In the case of predictive testing for childhood-onset conditions or conditions |
| for which childhood interventions will ameliorate future harm…parental authority|
| to determine medical treatment supersedes the minor’s preferences with regard to|
| liberty and privacy.” (p.238)                                                   |
| “Health-care providers should be cautious about providing such [predictive genetic]|
| testing to minors without the collaboration of their parents.” (p. 238)       |

| Timing of testing                                                               |
|--------------------------------------------------------------------------------|
| “Significant deference should be extended to parents regarding the timing       |
| of predictive genetic testing for childhood-onset conditions.” (p. 238)       |
| “The AAP and the ACMG continue to support the traditional professional         |
| recommendation to defer genetic testing for late-onset conditions until        |
| adulthood…” (p.238)                                                          |

| Access to results                                                             |
|-------------------------------------------------------------------------------|
| “The AAP and the ACMG believe that a request for the results of a genetic     |
| test by a mature adolescent should be given priority over his or her parents’|
| requests to conceal the information.” (p. 238)                                |
Table 3 (on next page)

Subset of Genes on the ACMG’s Minimum List for Reporting
Table 3. Subset of Genes on the ACMG’s Minimum List for Reporting

| Condition                                      | Genes                                    |
|------------------------------------------------|------------------------------------------|
| Hypertrophic Cardiomyopathy                    | MYBPC3, MYH7, TNNT2, TNNI3, TPM1, MYL3, ACTC1, PRKAG2 |
| Long QT Syndrome                               | KCNQ1, KCNH2, SCN5A                      |
| Marfan Syndrome and related disorders          | FBN1, TGFBR1, TGFBR2, SMAD3, ACTA2, MYLK, MYH11 |
Table 4 (on next page)

State Survey of Legislative Activity to Prevent SCD of athletes

Westlaw Next was used on June 19, 2013 to search for proposed and enacted legislation in the US related to sudden cardiac death prevention and athletic activity. The search was limited to the last 12 months of activity. The precise search terms used may have failed to uncover all of the legislative activity. OpenStates.org was used to verify the relevant subject matter contained in the bills located using Westlaw Next. Results specific to placement of automatic external defibrillators were not reported in this table. See also “Sudden Cardiac Arrest Legislation by State.” Available at http://www.simonsfund.org/sudden-cardiac-arrest-legislation-by-state/ Last accessed June 19, 2013.
### Table 4  State Survey of Legislative Activity to Prevent SCD of athletes

| State       | Proposed? | Enacted? | State       | Proposed? | Enacted? |
|-------------|-----------|----------|-------------|-----------|----------|
| Alabama     | Montana   |          | Alaska      | Nebraska  |          |
| Arizona     | Nevada    |          | Arkansas    | New Hampshire |          |
| California  | New Jersey|          | Colorado    | New Mexico|          |
| Connecticut | New York  |          | Delaware    |          | 2013 NY SB 80, intro. 1/9/13 |
| Delaware    | 2013 DE SB 108, intro. 6/5/13 |          | Florida     | North Dakota|          |
| Florida     |          |          | Georgia     |          | 2013 OH HB 180, intro. 5/28/13 |
| Hawaii      |          |          | Hawaii      |          | 2013 OK SB 39, intro. 2/4/13 |
| Hawaii      |          |          | Idaho       |          |          |
| Illinois    | 2013 SB 1274, intro. 1/31/13; 2013 HB 15, intro. 12/10/13 | Pennsylvania | Indiana    |          | Rhode Island |
| Indiana     | 2013 IN HB 1178, intro. 1/10/13 |          | Iowa        |          | South Carolina |
| Iowa        |          |          | Kansas      | South Dakota|          |
| Kansas      |          |          | Kentucky    |          | Tennessee |
| Louisiana   |          |          | Louisiana   | Texas     |          | 2013 TX SB 379, intro. 2/5/13 |
| Maine       |          |          | Maine       | Utah      |          |
| Maryland    |          |          | Massachusetts |          | Vermont |
| Michigan    | 2013 MI 4273, intro. 2/19/13 |          | Minnesota   | West Virginia|          |
| Minnesota   |          |          | Mississippi |          | Wisconsin |
| Missouri    |          |          | Missouri     | Wyoming   |          |

**Subtotal** | 5 | 0 | **Subtotal** | 5 | 1

| Total | 10 | 1 |

Westlaw Next was used on June 19, 2013 to search for proposed and enacted legislation in the US related to sudden cardiac death prevention and athletic activity. The search was limited to the last 12 months of activity. The precise search terms used may have failed to uncover all of the legislative activity. OpenStates.org was used to verify the relevant subject matter contained in the bills located using Westlaw Next. Results specific to placement of automatic external defibrillators were not reported in this table. See also “Sudden Cardiac Arrest Legislation by State.” Available at [http://www.simonsfund.org/sudden-cardiac-arrest-legislation-by-state/](http://www.simonsfund.org/sudden-cardiac-arrest-legislation-by-state/) Last accessed June 19, 2013.
Table 5 (on next page)

Excerpts of the Bethesda Conference #36 Guidelines
Table 5  Excerpts of the Bethesda Conference #36 Guidelines

| Condition          | Excerpts                                                                 |
|--------------------|--------------------------------------------------------------------------|
| HCM                | “1. Athletes with a probable or unequivocal clinical diagnosis of HCM *should be excluded from most competitive sports*, with the possible exception of those of low intensity (class IA). This recommendation is independent of age, gender, and phenotypic appearance, and *does not differ for those athletes with or without symptoms*, LV outflow obstruction, or prior treatment with drugs or major interventions with surgery, alcohol septal ablation, pacemaker, or implantable defibrillator.” (p. 1341, emphasis added)  
“2. Although the clinical significance and natural history of genotype positive-phenotype negative individuals remains unresolved, no compelling data are available at present with which to preclude these patients from competitive sports, particularly in the absence of cardiac symptoms or a family history of sudden death.” (p. 1341) |
| LQTS               | “2. Asymptomatic patients with baseline QT prolongation (QTc of 470 ms or more in males, 480 ms or more in females) should be restricted to class IA sports. The restriction limiting participation to class IA activities may be liberalized for the asymptomatic patient with genetically proven type 3 LQTS (LQT3).” (p.1362)  
“3. Patients with genotype-positive/phenotype-negative LQTS (i.e., identification of a LQTS-associated mutation in an asymptomatic individual with a nondiagnostic QTc) may be allowed to participate in competitive sports. Although the risk of sudden cardiac death is not zero in such individuals, there is no compelling data available to justify precluding these individuals (who are being identified with increasing frequency) from competitive activities. Because of the strong association between swimming and LQT1, *persons with genotype positive/phenotype-negative LQT1 should refrain from competitive swimming.*” (p. 1362, emphasis added) |
| MFS and related conditions | “1. Athletes with Marfan syndrome can participate in low and moderate static/low dynamic competitive sports (classes IA and IIA) if they do not have one or more of the following:  
a. aortic root dilatation …  
b. moderate-to-severe mitral regurgitation  
c. family history of dissection or sudden death in a Marfan relative…” (p. 1342)  
“3. *Athletes with Marfan syndrome*, familial aortic aneurysm or dissection, or congenital bicuspid aortic valve with any degree of ascending aortic enlargement… also *should not participate in sports that involve the potential for bodily collision.*” (p. 1342, emphasis added)  
1. Athletes with mild or moderate AR [aortic regurgitation], but with LV end-diastolic size that is normal or only mildly increased, consistent with that which may result solely from athletic training, can participate in all competitive sports. … Those with asymptomatic nonsustained ventricular tachycardia at rest or with exertion should participate in low-intensity competitive sports only (class IA)…” (p. 1337) |
Direct participant observation occurred in May 2011. The author purchased the four tests from US-based companies identified previously (Wagner and Royal 2012) and submitted her own DNA for analysis. Data on the following variables of interest were collected as part of the participant observation: the purchase process (e.g. informed consent requirements, details regarding terms of service and privacy policies); the DNA collection process (appearance of packaging; educational or marketing literature included; type of specimen required; supplies and instructions); timing issues (estimated wait times; lag times between dates of purchase, kit receipt, DNA sample arrival at company, and results receipt); and issues related to representation and return of results (e.g. media format used; type of information reported; manner in which risk scores or performance predictions were represented; descriptions of methods; readability of results material; and availability of interpretation support). Notably, the motivations, reactions, perceptions of satisfaction, comprehension of results, and other interesting facets of the consumer experience were not the focus of that study: rather, the research was conducted to permit a data-driven discussion of DTC sports-related genetic testing aspects that occur after customers click “purchase.” The information reported in Table 6 is a summary of those specific tests as provided in May 2011 using the author’s DNA. Tests may have changed. For example, as of late 2012, Athleticode was no longer offering this particular test.
Table 6 Summary of Genes Analyzed by Four DTC sports-related tests in 2011

| “SportsXFactor” by AIBiotech | “Body Scope Kit” by Athleticode | “Athletic Profile Test” by Warrior Roots | “Atlas First” by Atlas Sports Genetics |
|-------------------------------|---------------------------------|----------------------------------------|--------------------------------------|
| DIO1                          | COL1A1                          | ACTN3                                  | ACTN3                                |
| NOS3                          | COL51                           | HIF1                                    |                                      |
| IL6                           | COL12A1                         | MCT1                                    |                                      |
| ACTN3                         | GDF5                            | ADRB2                                   |                                      |
| PPARGC                        | MMP3                            | DIO1-D1A                                |                                      |
| VEGFR                         |                                 | DIO1-DIB                                |                                      |
| COL1A1                        |                                 | NOS3                                    |                                      |
| COL12A1                       |                                 | PPARGC1A                                |                                      |
| COL5A1                        |                                 | ACE                                     |                                      |
| MMP3                          |                                 | EPOR                                    |                                      |
| APOE                          |                                 |                                         |                                      |
| MYH7                          |                                 |                                         |                                      |
| MYBPC3                        |                                 |                                         |                                      |
| TNNT2                         |                                 |                                         |                                      |
| SCN5A                         |                                 |                                         |                                      |

*Direct participant observation occurred in May 2011. The author purchased the four tests from US-based companies identified previously (Wagner and Royal 2012) and submitted her own DNA for analysis. Data on the following variables of interest were collected as part of the participant observation: the purchase process (e.g. informed consent requirements, details regarding terms of service and privacy policies); the DNA collection process (appearance of packaging; educational or marketing literature included; type of specimen required; supplies and instructions); timing issues (estimated wait times; lag times between dates of purchase, kit receipt, DNA sample arrival at company, and results receipt); and issues related to representation and return of results (e.g. media format used; type of information reported; manner in which risk scores or performance predictions were represented; descriptions of methods; readability of results material; and availability of interpretation support). Notably, the motivations, reactions, perceptions of satisfaction, comprehension of results, and other interesting facets of the consumer experience were not the focus of that study: rather, the research was conducted to permit a data-driven discussion of DTC sports-related genetic testing aspects that occur after customers click “purchase.” The information reported in Table 6 is a summary of those specific tests as provided in May 2011 using the author’s DNA. Tests may have changed. For example, as of late 2012, Athleticode was no longer offering this particular test.